January 31, 2018 (US time) Eli Lilly and Company (Headquartered in Indiana, United States) (Lilly) announced in financial reporting to investors that the company’s EP4 Antagonist (Galliprant/grapiprant/RQ-00000007/AT-001) achieved 2017 fourth quarter sales of (US) $8 million, a 29 percent increase over third quarter sales, and (US) $23 million in 2017 fiscal year sales, which represents 12 percent of the US non-steroidal anti-inflammatory therapy animal health market.   

Please see Lilly’s “Investor” section on its corporate website for further details.